A cautionary tale illustrates how forging a deal with a Big Pharma can have unexpected and far-reaching tax consequences.
7d
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...
A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...
An NIH announcement Friday cutting billions in biomedical research, a federal funding review and DEI prohibitions have left ...
Ryan Finley explains why the IRS’s recent advice memorandum on periodic adjustments may signal a significant change in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback